http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021258625-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d84aa8c4818bda002eded1de6d318389
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56983
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-569
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-42
filingDate 2020-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc4dea9d5a01642f18a2ecf2f103ea85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9bf018ae85083f8d8652174601d41f6
publicationDate 2021-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2021258625-A1
titleOfInvention Anti-sar-cov-2 (covid-19) fully humanized monoclonal antibody, and preparation method therefor and application thereof
abstract The present invention provides an anti-SAR-COV-2 antibody, or an antigen-binding fragment thereof, and an application thereof, having a heavy chain complementary determining region as shown in SEQ ID Nos: 1-3, and a light chain complementary determining region as shown in SEQ ID Nos: 4-6. The antibody of the present invention is a humanized antibody, and has a low side effect, and high affinity and specificity.
priorityDate 2020-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399873
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21292785
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406714
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID171548
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406715
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15764346

Total number of triples: 40.